Skip to main content
Fig. 4 | Skeletal Muscle

Fig. 4

From: Pharmacology and macrophage modulation of HPGDS inhibitor PK007 demonstrate reduced disease severity in DMD-affected muscles of the mdx mouse model

Fig. 4

No significant change in average VO2 levels in PK007 and Vehicle-treated mdx mice. A-C denote VO2 levels of total movement activity over Days 1, 6 and 10 across the four treatment groups (Vehicle & PK007 treated mdx and WT groups). VO2 was analysed across 24 h and presented separately for the dark and light cycles. A displays no significant increase in VO2 levels at day 1 of treatment in a 24-h, dark and light cycle. B represents a significant difference between mdx and WT groups in VO2 levels in 24 h, dark and light cycle at treatment day 6. P values are denoted as follows: **** = p < 0.0001. C denotes a significant difference between mdx and WT groups in VO2 levels in 24 h, dark and light cycle at treatment day 10. P values are *** = 0.004 and **** = < 0.0001. Biological n = 6 between all treatment groups. P-values were calculated using a 2-way ANOVA with Tukey’s post hoc test

Back to article page